Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Keyword: Dysphagia

Publisher: GlobeNewswire

Published: May 21, 2026

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily p… [+14809 chars]

Read Full Story ↗

Related Content

Related Story Meeting the Aged Care Quality Standards – Food and nutrition

Npagroup.com.au
Related Story CGRP Inhibitors Market to Reach US$12.5 Bn by 2033 Expands with Rising Migraine Awareness and Advanced Targeted Therapies - Persistence Market Research

PRNewswire
Related Story Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Associated Press